| Pharmacological characterization of designer cathinones in vitro LD Simmler, TA Buser, M Donzelli, Y Schramm, LH Dieu, J Huwyler, ... British journal of pharmacology 168 (2), 458-470, 2013 | 743 | 2013 |
| Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naıve healthy volunteers FX Vollenweider, A Gamma, M Liechti, T Huber Neuropsychopharmacology 19 (4), 241-251, 1998 | 610 | 1998 |
| Acute effects of lysergic acid diethylamide in healthy subjects Y Schmid, F Enzler, P Gasser, E Grouzmann, KH Preller, FX Vollenweider, ... Biological psychiatry 78 (8), 544-553, 2015 | 460 | 2015 |
| Gender differences in the subjective effects of MDMA ME Liechti, A Gamma, FX Vollenweider Psychopharmacology 154, 161-168, 2001 | 453 | 2001 |
| The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation KH Preller, M Herdener, T Pokorny, A Planzer, R Kraehenmann, ... Current Biology 27 (3), 451-457, 2017 | 382 | 2017 |
| MDMA enhances emotional empathy and prosocial behavior CM Hysek, Y Schmid, LD Simmler, G Domes, M Heinrichs, C Eisenegger, ... Social cognitive and affective neuroscience 9 (11), 1645-1652, 2014 | 376 | 2014 |
| Acute psychological effects of 3, 4-methylenedioxymethamphetamine (MDMA,“Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram ME Liechti, C Baumann, A Gamma, FX Vollenweider Neuropsychopharmacology 22 (5), 513-521, 2000 | 341 | 2000 |
| Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens A Rickli, OD Moning, MC Hoener, ME Liechti European Neuropsychopharmacology 26 (8), 1327-1337, 2016 | 300 | 2016 |
| Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signalling ME Liechti Swiss medical weekly 145, w14043, 2015 | 295 | 2015 |
| Psychological and physiological effects of MDMA (“Ecstasy”) after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans ME Liechti, MR Saur, A Gamma, D Hell, FX Vollenweider Neuropsychopharmacology 23 (4), 396-404, 2000 | 292 | 2000 |
| LSD acutely impairs fear recognition and enhances emotional empathy and sociality PC Dolder, Y Schmid, F Müller, S Borgwardt, ME Liechti Neuropsychopharmacology 41 (11), 2638-2646, 2016 | 290 | 2016 |
| Modern clinical research on LSD ME Liechti Neuropsychopharmacology 42 (11), 2114-2127, 2017 | 270 | 2017 |
| To dope or not to dope: neuroenhancement with prescription drugs and drugs of abuse among Swiss university students LJ Maier, ME Liechti, F Herzig, MP Schaub PloS one 8 (11), e77967, 2013 | 269 | 2013 |
| Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies ME Liechti, FX Vollenweider Human Psychopharmacology: Clinical and Experimental 16 (8), 589-598, 2001 | 267 | 2001 |
| Long-lasting subjective effects of LSD in normal subjects Y Schmid, ME Liechti Psychopharmacology 235, 535-545, 2018 | 239 | 2018 |
| Monoamine transporter and receptor interaction profiles of a new series of designer cathinones LD Simmler, A Rickli, MC Hoener, ME Liechti Neuropharmacology 79, 152-160, 2014 | 233 | 2014 |
| Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence ME Liechti, L Lhuillier, K Kaupmann, A Markou Journal of Neuroscience 27 (34), 9077-9085, 2007 | 217 | 2007 |
| Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones A Rickli, MC Hoener, ME Liechti European Neuropsychopharmacology 25 (3), 365-376, 2015 | 216 | 2015 |
| Designer drugs: mechanism of action and adverse effects D Luethi, ME Liechti Archives of toxicology 94 (4), 1085-1133, 2020 | 214 | 2020 |
| Alterations of consciousness and mystical-type experiences after acute LSD in humans ME Liechti, PC Dolder, Y Schmid Psychopharmacology 234, 1499-1510, 2017 | 212 | 2017 |
